Advertisement

DANCR Induces Cisplatin Resistance of Triple-Negative Breast Cancer by KLF5/p27 Signaling

  • Anchen Su
    Affiliations
    The First Hospital of Lanzhou University, Gansu International Scientific and Technological Cooperation Base of Reproductive Medicine Transformation Application, Lanzhou, China
    Search for articles by this author
  • Kun Yao
    Affiliations
    Gansu Provincial Hospital, Lanzhou, China
    Search for articles by this author
  • Hanru Zhang
    Affiliations
    Gynecology and Obstetrics, Gansu Provincial Maternity and Child Care Hospital, Lanzhou, China
    Search for articles by this author
  • Yiqing Wang
    Affiliations
    The First Hospital of Lanzhou University, Gansu International Scientific and Technological Cooperation Base of Reproductive Medicine Transformation Application, Lanzhou, China
    Search for articles by this author
  • Haibo Zhang
    Correspondence
    Address correspondence to Jianming Tang, The First Hospital of Lanzhou University, Gansu International Scientific and Technological Cooperation Base of Reproductive Medicine Transformation Application, Lanzhou 730000, China; or Haibo Zhang, Oncology Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
    Affiliations
    Oncology Center, Department of Radiation Oncology, Zhejiang Provincial People 's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
    Search for articles by this author
  • Jianming Tang
    Correspondence
    Address correspondence to Jianming Tang, The First Hospital of Lanzhou University, Gansu International Scientific and Technological Cooperation Base of Reproductive Medicine Transformation Application, Lanzhou 730000, China; or Haibo Zhang, Oncology Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
    Affiliations
    The First Hospital of Lanzhou University, Gansu International Scientific and Technological Cooperation Base of Reproductive Medicine Transformation Application, Lanzhou, China
    Search for articles by this author
Published:December 09, 2022DOI:https://doi.org/10.1016/j.ajpath.2022.11.007
      An increasing body of evidence suggests that long noncoding RNAs play critical roles in human cancer. Breast cancer is a heterogeneous disease and the potential involvement of long noncoding RNAs in breast cancer remains poorly understood. Herein, researchers identified a long noncoding RNA, DANCR, which promotes cisplatin chemoresistance in triple-negative breast cancer cells. Mechanistically, DANCR could bind to Krüppel-like factor 5 (KLF5) and induce acetylation of KLF5 at lysine 369 (K369), and DANCR knockdown resulted in down-regulation of KLF5 protein levels. Furthermore, researchers found that the DANCR/KLF5 signaling pathway induced hypersensitivity to cisplatin in chemoresistant patients by inhibiting p27 transcription. In summary, researcher's study reinforces the potential presence of a growth regulatory network found in triple-negative breast cancer cells, and a DANCR/KLF5/p27 signaling pathway was documented in the present study that mediates cisplatin chemoresistance in triple-negative breast cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lehmann B.D.
        • Bauer J.A.
        • Chen X.
        • Sanders M.E.
        • Chakravarthy A.B.
        • Shyr Y.
        • Pietenpol J.A.
        Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
        J Clin Invest. 2011; 121: 2750-2767
        • Carey L.A.
        • Dees E.C.
        • Sawyer L.
        • Gatti L.
        • Moore D.T.
        • Collichio F.
        • Ollila D.W.
        • Sartor C.I.
        • Graham M.L.
        • Perou C.M.
        The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
        Clin Cancer Res. 2007; 13: 2329-2334
        • Dent R.
        • Trudeau M.
        • Pritchard K.I.
        • Hanna W.M.
        • Kahn H.K.
        • Sawka C.A.
        • Lickley L.A.
        • Rawlinson E.
        • Sun P.
        • Narod S.A.
        Triple-negative breast cancer: clinical features and patterns of recurrence.
        Clin Cancer Res. 2007; 13: 4429-4434
        • Bardia A.
        • Parton M.
        • Kümmel S.
        • Estévez L.G.
        • Huang C.S.
        • Cortés J.
        • Ruiz-Borrego M.
        • Telli M.L.
        • Martin-Martorell P.
        • López R.
        • Beck J.T.
        • Ismail-Khan R.
        • Chen S.C.
        • Hurvitz S.A.
        • Mayer I.A.
        • Carreon D.
        • Cameron S.
        • Liao S.
        • Baselga J.
        • Kim S.B.
        Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial.
        J Clin Oncol. 2018; ([Epub ahead of print] doi:)
        • Dent R.
        • Oliveira M.
        • Isakoff S.J.
        • Im S.A.
        • Espié M.
        • Blau S.
        • Tan A.R.
        • Saura C.
        • Wongchenko M.J.
        • Xu N.
        • Bradley D.
        • Reilly S.J.
        • Mani A.
        • Kim S.B.
        • LOTUS investigators
        Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
        Breast Cancer Res Treat. 2021; 189: 377-386
        • Tang J.
        • Zhong G.
        • Zhang H.
        • Yu B.
        • Wei F.
        • Luo L.
        • Kang Y.
        • Wu J.
        • Jiang J.
        • Li Y.
        • Wu S.
        • Jia Y.
        • Liang X.
        • Bi A.
        LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA.
        Cell Death Dis. 2018; 9: 1167
        • Liu Y.
        • Zhang M.
        • Liang L.
        • Li J.
        • Chen Y.X.
        Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer.
        Int J Clin Exp Pathol. 2015; 8: 11480-11484
        • Yuan S.X.
        • Wang J.
        • Yang F.
        • Tao Q.F.
        • Zhang J.
        • Wang L.L.
        • Yang Y.
        • Liu H.
        • Wang Z.G.
        • Xu Q.G.
        • Fan J.
        • Liu L.
        • Sun S.H.
        • Zhou W.P.
        Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1.
        Hepatology. 2016; 63: 499-511
        • Jiang N.
        • Wang X.
        • Xie X.
        • Liao Y.
        • Liu N.
        • Liu J.
        • Miao N.
        • Shen J.
        • Peng T.
        lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition.
        Cancer Lett. 2017; 405: 46-55
        • Liu R.
        • Zheng H.Q.
        • Zhou Z.
        • Dong J.T.
        • Chen C.
        KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization.
        J Biol Chem. 2009; 284: 16791-16798
        • Zheng H.Q.
        • Zhou Z.
        • Huang J.
        • Chaudhury L.
        • Dong J.T.
        • Chen C.
        Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.
        Oncogene. 2009; 28: 3702-3713
        • Liu R.
        • Shi P.
        • Nie Z.
        • Liang H.
        • Zhou Z.
        • Chen W.
        • Chen H.
        • Dong C.
        • Yang R.
        • Liu S.
        • Chen C.
        Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression.
        Theranostics. 2016; 6: 533-544
        • Shi P.
        • Liu W.
        • Tala
        • Wang H.
        • Li F.
        • Zhang H.
        • Wu Y.
        • Kong Y.
        • Zhou Z.
        • Wang C.
        • Chen W.
        • Liu R.
        • Chen C.
        Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation.
        Cell Discov. 2017; 3: 17010
        • Ben-Porath I.
        • Thomson M.W.
        • Carey V.J.
        • Ge R.
        • Bell G.W.
        • Regev A.
        • Weinberg R.A.
        An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.
        Nat Genet. 2008; 40: 499-507
        • Tong D.
        • Czerwenka K.
        • Heinze G.
        • Ryffel M.
        • Schuster E.
        • Witt A.
        • Leodolter S.
        • Zeillinger R.
        Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer.
        Clin Cancer Res. 2006; 12: 2442-2448
        • Takagi K.
        • Miki Y.
        • Onodera Y.
        • Nakamura Y.
        • Ishida T.
        • Watanabe M.
        • Inoue S.
        • Sasano H.
        • Suzuki T.
        Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens.
        Endocr Relat Cancer. 2012; 19: 741-750
        • Liu R.
        • Chen H.
        • Zhao P.
        • Chen C.H.
        • Liang H.
        • Yang C.
        • Zhou Z.
        • Zhi X.
        • Liu S.
        • Chen C.
        Mifepristone derivative FZU-00,003 suppresses triple-negative breast cancer cell growth partially via miR-153-KLF5 axis.
        Int J Biol Sci. 2020; 16: 611-619
        • Wu G.
        • Zhou H.
        • Li D.
        • Zhi Y.
        • Liu Y.
        • Li J.
        • Wang F.
        LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis.
        Exp Cell Res. 2020; 396: 112331
        • Tang J.
        • Li Y.
        • Sang Y.
        • Yu B.
        • Lv D.
        • Zhang W.
        • Feng H.
        LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling.
        Oncogene. 2018; 37: 4723-4734
        • Tao R.
        • Zhang B.
        • Li Y.
        • King J.L.
        • Tian R.
        • Xia S.
        • Schiavon C.R.
        • Dong J.T.
        HDAC-mediated deacetylation of KLF5 associates with its proteasomal degradation.
        Biochem Biophys Res Commun. 2018; 500: 777-782
        • Guo P.
        • Zhao K.W.
        • Dong X.Y.
        • Sun X.
        • Dong J.T.
        Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells.
        J Biol Chem. 2009; 284: 18184-18193
        • Zheng B.
        • Han M.
        • Shu Y.N.
        • Li Y.J.
        • Miao S.B.
        • Zhang X.H.
        • Shi H.J.
        • Zhang T.
        • Wen J.K.
        HDAC2 phosphorylation-dependent Klf5 deacetylation and RARα acetylation induced by RAR agonist switch the transcription regulatory programs of p21 in VSMCs.
        Cell Res. 2011; 21: 1487-1508
        • Wang C.
        • Nie Z.
        • Zhou Z.
        • Zhang H.
        • Liu R.
        • Wu J.
        • Qin J.
        • Ma Y.
        • Chen L.
        • Li S.
        • Chen W.
        • Li F.
        • Shi P.
        • Wu Y.
        • Shen J.
        • Chen C.
        The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27 Kip1.
        Oncotarget. 2015; 6: 17685-17697
        • Dasari S.
        • Tchounwou P.B.
        Cisplatin in cancer therapy: molecular mechanisms of action.
        Eur J Pharmacol. 2014; 740: 364-378
        • Florea A.M.
        • Büsselberg D.
        Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.
        Cancers (Basel). 2011; 3: 1351-1371
        • Altaha R.
        • Liang X.
        • Yu J.J.
        • Reed E.
        Excision repair cross complementing-group 1: gene expression and platinum resistance (review) parameters in human breast cancer.
        Int J Mol Med. 2004; 14: 959-970
        • Siddik Z.H.
        Cisplatin: mode of cytotoxic action and molecular basis of resistance.
        Oncogene. 2003; 22: 7265-7279
        • Catanzaro D.
        • Gaude E.
        • Orso G.
        • Giordano C.
        • Guzzo G.
        • Rasola A.
        • Ragazzi E.
        • Caparrotta L.
        • Frezza C.
        • Montopoli M.
        Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death.
        Oncotarget. 2015; 6: 30102-30114
        • Liu R.
        • Zhou Z.
        • Zhao D.
        • Chen C.
        The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.
        Mol Endocrinol. 2011; 25: 1137-1144
        • Ziemer L.T.
        • Pennica D.
        • Levine A.J.
        Identification of a mouse homolog of the human BTEB2 transcription factor as a beta-catenin-independent Wnt-1-responsive gene.
        Mol Cell Biol. 2001; 21: 562-574
        • Taneyhill L.
        • Pennica D.
        Identification of Wnt responsive genes using a murine mammary epithelial cell line model system.
        BMC Dev Biol. 2004; 4: 6
        • Dong J.T.
        • Chen C.
        Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases.
        Cell Mol Life Sci. 2009; 66: 2691-2706
        • Li Z.
        • Dong J.
        • Zou T.
        • Du C.
        • Li S.
        • Chen C.
        • Liu R.
        • Wang K.
        Dexamethasone induces docetaxel and cisplatin resistance partially through upregulating Krüppel-like factor 5 in triple-negative breast cancer.
        Oncotarget. 2017; 8: 11555-11565
        • Fernández de Mattos S.
        • Villalonga P.
        • Clardy J.
        • Lam E.W.
        FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells.
        Mol Cancer Ther. 2008; 7: 3237-3246
        • Dong Z.
        • Yang L.
        • Lai D.
        KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression.
        Cell Prolif. 2013; 46: 425-435
        • Gong T.
        • Cui L.
        • Wang H.
        • Wang H.
        • Han N.
        Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1alpha-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
        J Transl Med. 2018; 16: 164
        • Li Q.
        • Wang X.
        • Zhou L.
        • Jiang M.
        • Zhong G.
        • Xu S.
        • Zhang M.
        • Zhang Y.
        • Liang X.
        • Zhang L.
        • Tang J.
        • Zhang H.
        A positive feedback loop of long noncoding RNA LINC00152 and KLF5 facilitates breast cancer growth.
        Front Oncol. 2021; 11: 619915
        • Wang S.
        • Jiang M.
        The long non-coding RNA-DANCR exerts oncogenic functions in non-small cell lung cancer via miR-758-3p.
        Biomed Pharmacother. 2018; 103: 94-100
        • Wang Y.
        • Lu Z.
        • Wang N.
        • Feng J.
        • Zhang J.
        • Luan L.
        • Zhao W.
        • Zeng X.
        Long non-coding RNA DANCR promotes colorectal cancer proliferation and metastasis via miR-577 sponging.
        Exp Mol Med. 2018; 50: 1-17
        • Jia J.
        • Li F.
        • Tang X.S.
        • Xu S.
        • Gao Y.
        • Shi Q.
        • Guo W.
        • Wang X.
        • He D.
        • Guo P.
        Long non-coding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3.
        Oncotarget. 2016; 7: 37868-37881
        • Ma Y.
        • Zhou G.
        • Li M.
        • Hu D.
        • Zhang L.
        • Liu P.
        • Lin K.
        Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway.
        Neurochem Int. 2018; 118: 233-241
        • Alkarain A.
        • Slingerland J.
        Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.
        Breast Cancer Res. 2004; 6: 13-21
        • Jia X.
        • Shi L.
        • Wang X.
        • Luo L.
        • Ling L.
        • Yin J.
        • Song Y.
        • Zhang Z.
        • Qiu N.
        • Liu H.
        • Deng M.
        • He Z.
        • Li H.
        • Zheng G.
        KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation.
        Cell Death Dis. 2019; 10: 373